Simone C. Oostindie

Leiden University Medical Center — Netherlands

Medicine · Health Sciences

10h-index887citations18works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(14), Chronic Lymphocytic Leukemia Research(7), Lymphoma Diagnosis and Treatment(5), Glycosylation and Glycoproteins Research(5), Complement system in diseases(5)

Publications18 total

Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies
Blood·2022· 6 cited
Logic-gated antibody pairs that selectively act on cells co-expressing two antigens
Nature Biotechnology·2022· 41 citedOpen Access
Avidity in antibody effector functions and biotherapeutic drug design
Nature Reviews Drug Discovery·2022· 225 citedOpen Access
Cyton2: A Model of Immune Cell Population Dynamics That Includes Familial Instructional Inheritance
Frontiers in Bioinformatics·2021· 16 citedOpen Access
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
HemaSphere·2020· 12 citedOpen Access
Abstract 4544: Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models
Cancer Research·2020
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
Blood Cancer Journal·2020· 68 citedOpen Access
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
EBioMedicine·2020· 159 citedOpen Access
Carbamylation reduces the capacity of IgG for hexamerization and complement activation
Clinical & Experimental Immunology·2019· 18 citedOpen Access
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
Haematologica·2019· 61 citedOpen Access
Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models
Blood·2018
Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples
Blood·2018· 1 cited
Hexamerization-enhanced CD37 and CD20 antibodies synergize in CDC to kill patient-derived CLL cells with unprecedented potency
Molecular Immunology·2018· 1 cited
Impact of carbamylation on IgG mediated complement activation
Molecular Immunology·2017
Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions
Immunobiology·2016· 3 cited
Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions
The Journal of Immunology·2016· 58 citedOpen Access
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
PLoS Biology·2016· 218 citedOpen Access
Fungal polysaccharides recognized by animal immune cells differentially induce Th17 and Th1 responses
Socio-Environmental Systems Modeling·2011Open Access

Frequent Co-authors

Paul W.H.I. Parren(12), Janine Schuurman(11), Frank J. Beurskens(11), Esther C.W. Breij(9), Margaret A. Lindorfer(7), Ronald P. Taylor(7), Hilma J. van der Horst(6), Martine E.D. Chamuleau(6), Tuna Mutis(6), Kristin Strumane(5), Marije B. Overdijk(5), Sandra Verploegen(4), Erika M. Cook(4), Clive S. Zent(4), Richard Burack(4), Rob N. de Jong(3), Patrick Engelberts(3), A. Kate Sasser(3), Bart de Jong(2), Edward N. van den Brink(2)